Patients in the group had various GI cancers including:
• Colon cancer: 48 percent
• Rectal cancer: 42.8 percent
• Esophageal cancer: 10.2 percent
The subgroup of patients who took aspirin had a five-year survival rate of 75 percent, while the patients who did not take aspirin had a five-year survival rate of 40 percent.
More articles on gastroenterology:
FDA approves new CRC drug
Beyond patient care: The biggest challenges in GI
4 GI physicians in the news – Sept. 25, 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
